Materialise: Strong Q3 Results Despite Ongoing Market Headwinds
- Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace.
- Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale.
- The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue.
- Despite the stock moving higher in recent weeks, Materialise remains deeply undervalued.
Monty Rakusen
Materialise (NASDAQ:MTLS) recorded strong results in the third quarter, primarily due to its Medical segment. This, despite a challenging demand environment and headwinds from a business model transition in the Software segment. While the soft demand environment is likely to
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
